Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 4/20 | 0.58 |
| ▸ | CES1 | P23141 | 4/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6757863 | 1.00 | CES2 (0.58) | CES2CES1KDM4EDUSP3MEN1 | |
| SCHEMBL6761739 | 1.00 | CES2 (0.58) | CES2CES1KDM4EDUSP3MEN1 | |
| SCHEMBL6757875 | 0.90 | FAAH (0.58) | DUSP3MEN1KMT2ALMNAMAPT | |
| SCHEMBL3621423 | 0.86 | CES2 (0.60) | CES2CES1 | |
| SCHEMBL4778226 | 0.86 | CES2 (0.60) | CES2CES1 | |
| SCHEMBL16449208 | 0.84 | CES2 (0.58) | CES2CES1KDM4EDUSP3MEN1 | |
| SCHEMBL16449209 | 0.84 | CES2 (0.58) | CES2CES1KDM4EDUSP3MEN1 | |
| SCHEMBL16449177 | 0.84 | CES2 (0.58) | CES2CES1KDM4EDUSP3MEN1 | |
| SCHEMBL16449174 | 0.84 | CES2 (0.58) | CES2CES1KDM4EDUSP3MEN1 | |
| SCHEMBL16449175 | 0.82 | CES2 (0.56) | CES2CES1KDM4EDUSP3MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6444660-B1 | DEXAMETHASONE COVALENTLY BONDED TO A LIPID MOIETY VIA A LINKING GROUP | IMARX THERAPEUTICS, INC. | 2002-09-03 | — | — | US | claimed |
| WO-1998050040-A1 | NOVEL LIPID SOLUBLE STEROID PRODRUGS | IMARX PHARMACEUTICAL CORP. (US) | 1998-11-12 | — | — | WO | claimed |
| WO-2024133635-A1 | COMPOSITION | BIONTECH DELIVERY TECHNOLOGIES GMBH (DE) | 2024-06-27 | — | — | WO | disclosed |
| US-6716412-B2 | LYSIS BLOOD CLOTS | IMARX THERAPEUTICS, INC. | 2004-04-06 | — | — | US | disclosed |
| US-6548047-B1 | Using lecithin, cephalin filled with gases; scanning; medical diagnosis | BRISTOL-MYERS SQUIBB MEDICAL IMAGING, INC. | 2003-04-15 | — | — | US | disclosed |
| US-6444660-B1 | DEXAMETHASONE COVALENTLY BONDED TO A LIPID MOIETY VIA A LINKING GROUP | IMARX THERAPEUTICS, INC. | 2002-09-03 | — | — | US | disclosed |
| US-20010031243-A1 | Novel methods of ultrasound treatment using gas or gaseous precursor-filled compositions | IMARX PHARMACEUTICAL CORP. | 2001-10-18 | — | — | US | disclosed |
| US-6090800-A | REACTION PRODUCT CONTAINING DEXAMETHASONE | IMARX PHARMACEUTICAL CORP. (US) | 2000-07-18 | — | — | US | disclosed |
| EP-0901793-A1 | Thermal preactivation of gaseous precursor filled compositions | IMARX PHARMACEUTICAL CORP. (US) | 1999-03-17 | — | — | EP | disclosed |
| WO-1998050040-A1 | NOVEL LIPID SOLUBLE STEROID PRODRUGS | IMARX PHARMACEUTICAL CORP. (US) | 1998-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010031243-A1 | Novel methods of ultrasound treatment using gas or gaseous precursor-filled compositions | SON, HYOU1, GCG | CES2 1877/4885CES1 2467/4885KDM4E 4508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.